Innovation Pharmaceuticals Inc (IPIX)

[olden_grumpini]

Has anyone heard of proxalutamide being developed by Kintor Pharmaceutical Ltd? I hadn't heard about it until this morning. Come to find out they have five Phase 3 clinical trials for COVID. This is the kind of competition that exists for IPIX.

One of their trials completed recently: Proxalutamide Treatment for Hospitalized COVID-19 Patients (Phase 3)
Study had 645 participants and was done in Brazil. The study start date was February 1, 2021 and results were posted June 23, 2021. The drug is administered as a pill. Study has results posted so you can dig into the outcomes, SAEs, etc. The last outcome date was 28 days -- no 60 day phone call for these guys.

A preprint of their paper has been posted: Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial.

Takeaway from the preprint:

Findings 
A total of 645 patients were randomized (317 received proxalutamide, 328 placebo) and underwent intention-to-treat analysis. The 14-day median ordinal scale score in the proxalutamide group was 1 (interquartile range [IQR]=1–2) versus 7 (IQR=2–8) for placebo, P<0.001. The 14-day recovery rate was 81.4% for proxalutamide and 35.7% for placebo (recovery ratio, 2.28; 95% CI 1.95–2.66 [P<0.001]). The 28-day all-cause mortality rate was 11.0% for proxalutamide versus 49.4% for placebo (hazard ratio, 0.16; 95% CI 0.11–0.24). The median post-randomization time to recovery was 5 days (IQR=3– 8) for proxalutamide versus 10 days (IQR=6–15) for placebo.

Interpretation 
Hospitalized COVID-19 patients not requiring mechanical ventilation receiving proxalutamide had a 128% higher recovery rate than those treated with placebo. All-cause mortality was reduced by 77.7% over 28 days.

 
People were throwing around potential revenue numbers for brilacidin. Does this drug have any impact on brilacidin's revenue potential?